To include your compound in the COVID-19 Resource Center, submit it here.

Juno licenses gamma secretase inhibitor, related IP

Juno Therapeutics Inc. (NASDAQ:JUNO) announced on Wednesday a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE